Glaukos – New iDose Implant and Epioxa Procedure Should Significantly Boost Results for Eye Care Specialist!
Reading Time: 1 minute
Business Driver: Glaukos (GKOS) specializes in minimally invasive procedures and micro-implants for the treatment of glaucoma, which is considered one of the leading causes of blindness. Among micro-implants, Glaukos is a leading provider in this segment with its iStent inject W, which reduces intraocular pressure in patients diagnosed with primary open-angle glaucoma. With the FDA's approval of the eye implant IDose TR, Glaukos achieved a significant breakthrough at the end of 2023. Fresh momentum is promised by Glaukos's newly developed Epioxa...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
